Clinical, patient and estimated cost benefits of proactive management versus reactive management with calcipotriol/betamethasone dipropionate foam for the treatment of plaque psoriasis in Finland

References

• Goff KL, Karimkhani C, Boyers LN, et al. The global burden of psoriatic skin disease. Br J Dermatol. 2015;172(6):1665–1668.
   PubMed Web of Science ®Google Scholar
• Global Psoriasis Atlas. Global Psoriasis Atlas 2017. [cited 2021 April 21]. Available from: https://www.globalpsoriasisatlas.org/.
   Google Scholar
• Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271.
   PubMed Web of Science ®Google Scholar
• de Korte J, Mombers FMC, Bos JD, et al. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004;9(2):140–147.
   PubMed Web of Science ®Google Scholar
• Harvima RJ, Viinamäki H, Harvima IT, et al. Association of psychic stress with clinical severity and symptoms of psoriatic patients. Acta Derm Venereol. 1996;76(6):467–471.
   PubMed Web of Science ®Google Scholar
• Liluashvili S, Kituashvili T. Dermatology life quality index and disease coping strategies in psoriasis patients. Postepy Dermatol Alergol. 2019;XXXVI(4):419–424.
   Google Scholar
• National Institute for Health and Care Excellence. Psoriasis: assessment and management (Clinical Guideline CG153). 2017. [cited 2021 June 21]. Available from: https://nice.org.uk/guidance/cg153.
   Google Scholar
• Duodecim of the Finnish Medical Association and the Finnish Dermatological Association. Current care recommendations: psoriasis and psoriatic arthritis. Finland: Duodecim; 2020.
   Google Scholar
• Segaert S, Calzavara-Pinton P, de la Cueva P, et al. Long-term topical management of psoriasis: the road ahead. J Dermatolog Treat. 2020;1–10.
   PubMed Web of Science ®Google Scholar
• Bark C, Brown C, Svangren P. Systematic literature review of long-term efficacy data for topical psoriasis treatments. J Dermatolog Treat. 2021;1–35.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris 2020. [cited 2021 May 04]. Available from: https://clinicaltrials.gov/ct2/show/NCT02899962.
   Google Scholar
• Lebwohl M, Kircik L, Lacour JP, et al. Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). J Am Acad Dermatol. 2020;84(5):1269–1277.
   PubMed Web of Science ®Google Scholar
• Husted JA, Gladman DD, Long JA, et al. A modified version of the health assessment questionnaire (HAQ) for psoriatic arthritis. Clin Exp Rheumatol. 1995;13(4):439–443.
   PubMed Web of Science ®Google Scholar
• British Association of Dermatologists. Psoriasis Area and Severity Index (PASI) worksheet [cited 2021 May 06]. Available from: https://www.bad.org.uk/shared/get-file.ashx?id=1654&itemtype=document.
   Google Scholar
• Finlay AY, Khan GK. Dermatology life quality index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216.
   PubMed Web of Science ®Google Scholar
• British Association of Dermatologists. Dermatology Life Quality Index (DLQI) [cited 2021 May 06]. Available from: https://www.bad.org.uk/library-media/documents/Dermatology%20Life%20Quality%20Iindex%20(DLQI)%20-%2001.10.12.pdf.
   Google Scholar
• Phàm B, Cranney A, Boers M, et al. Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials. J Rheumatol. 1999;26 3:712–716.
   Web of Science ®Google Scholar
• Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris-A randomized phase II study. J Dermatolog Treat. 2016;27(2):120–127.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, phase 2 study. J Clin Aesthet Dermatol. 2016;9(2):34–41.
   PubMedGoogle Scholar
• Leonardi C, Yamauchi P, Pariser D, et al. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris–a Randomized Phase III Study (PSO-FAST). J Drugs Dermatol. 2015;14(12):1468–1477.
   PubMed Web of Science ®Google Scholar
• Paul CS, Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017;31(1):1468–3083.
   PubMed Web of Science ®Google Scholar
• Takhar A, Thoning H, Nyholm N, et al. The effect on body surface area of proactive versus reactive management of psoriasis in the PSO-LONG study. J Drugs Dermatol. 2021;20(5): 567–570.
   PubMed Web of Science ®Google Scholar
• Hjalte F, Asseburg C, Fau - Tennvall GR, Tennvall GR. Cost-effectiveness of a barrier-strengthening moisturizing cream as maintenance therapy vs. no treatment after an initial steroid course in patients with atopic dermatitis in Sweden–with model applications for Denmark, Norway and Finland. J Eur Acad Dermatol Venereo. 2010;24(4):474–480.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Lacour J, Liljedahl M. Long term proactive management of psoriasis vulgaris with fixed dose combination of calcipotriene 0.005% and betamethasone dipropionate 0.064% foam: results of a Phase III randomized controlled trial. American Academy of Dermatology Annual Meeting; Denver, Colorado, USA; 2020.
   Google Scholar
• Balak DMW, Carrascosa JM, Gregoriou S, et al. Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries. J Dermatolog Treat. 2020;6:1–8.
   Google Scholar
• Takhar A, Th Petersen B, Salih F, et al. Cost-effectiveness of proactive management versus reactive management with calcipotriol/betamethasone dipropionate foam for treatment of psoriasis vulgaris in the UK. Virtual ISPOR, Europe; 2020;23(2):S734–S735.
   Google Scholar
• Dähnhardt D, Bastian M, Dähnhardt-Pfeiffer S, et al. Comparing the effects of proactive treatment with tacrolimus ointment and mometasone furoate on the epidermal barrier structure and ceramide levels of patients with atopic dermatitis. J Dermatolog Treat. 2020;3:1–9.
   Google Scholar
• Wollenberg A, Reitamo S, Girolomoni G, for the European Tacrolimus Ointment Study Group, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy. 2008;63(7):742–750.
   Web of Science ®Google Scholar
• Healy E, Bentley A, Fidler C, et al. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. Br J Dermatol. 2011;164(2):387–395.
   PubMed Web of Science ®Google Scholar
• Kela. Medicinal Products Database Finland 2021. Available from: https://asiointi.kela.fi/laakekys_app/LaakekysApplication?kieli=en.
   Google Scholar
• Kapiainen S, Väisänen A, Haula T. Terveyden- ja sosiaalihuollon yksikkökustannukset Suomessa vuonna 2011. Helsinki, Finland: Finnish Institute for Health and Welfare; 2014.
   Google Scholar
• Finland S. Statistics Finland - Value of Money Converter 2021. Available from: https://www.stat.fi/tup/laskurit/rahanarvonmuunnin_en.html.
   Google Scholar